1. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. (13th March 2019) Authors: Trédan, O; Wang, Q; Pissaloux, D; Cassier, P; de la Fouchardière, A; Fayette, J; Desseigne, F; Ray-Coquard, I; de la Fouchardière, C; Frappaz, D; Heudel, P -E; Bonneville-Levard, A; Fléchon, A; Sarabi, M; Guibert, P; Bachelot, T; Pérol, M; You, B; Bonnin, N; Collard, O Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 757 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1065PTOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC. (23rd October 2018) Authors: Even, C; Daste, A; Saada-Bouzid, E; Fayette, J; Kaminsky-Forrett, M-C; Zanetta, S; Prevost, A; Lefebvre, G; Borel, C; Cupissol, D; Huguet, F; Delord, J-P; Baste Rotllan, N; Delaye, J; Jallut, I; Vintonenko, N; Bourhis, J; Guigay, J; Texier, M; Auperin, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). (23rd October 2018) Authors: Haddad, R; Wong, D J; Guo, Y; Fayette, J; Cohen, E E W; Kowgier, M; Sandler, A; Matheny, C; Kabbinavar, F; Raben, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1347TiPProof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice. (23rd October 2018) Authors: Mastier, C; de la Fouchardière, C; Fayette, J; Sarabi, M; Heudel, P; Coulon, A; Banaste, N; Mercier-Bischoff, E; Barma, M; Brahmi, M; Cassier, P; Couchon Thaunat, S; Eberst, L; Fournier-Garin, G; Metral, P; Pilleul, F; Blay, J-Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03). (15th December 2019) Authors: Fayette, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗